Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma
This is an open label, multicenter, single-arm phase II trial with primary eqirubicine-oxaliplatin-capecitabine chemotherapy and concurrent Pmab in patients with resectable, histologically proven gastric or esophageal cancer.
KRAS Wild Type|Resectable Type II Gastric Adenocarcinoma
DRUG: Epirubicine, Oxaliplatin, Capecitabine, Panitumumab
Efficacy, Proportion of patients with T0 ant T1 disease after neoadjuvant combined chemoimmunotherapy|Safety, Proportion of patients with grade 4 diarrhea
Histopathological response, rate of complete pathological response|overall survival after one year|Progression free survival after one year|Proportion of patients completing 3 treatment cycles|Safety, NCI CTCAE v.3
This is an open label, multicenter, single-arm phase II trial with primary eqirubicine-oxaliplatin-capecitabine chemotherapy and concurrent Pmab in patients with resectable, histologically proven gastric or esophageal cancer.